Ribupatide: all 32 studies that test it

Page 1 of 1. Open to participants first (9), then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate the Impact of Renal Impairment on the Pharmacokinetics (PK) of RibupatideRecruitingNCT07793929Phase 1
• A Trial of Ribupatide Injection in Participants With Obesity and Knee OsteoarthritisNot yet recruitingNCT07709910Phase 3
• A Study of HRS-4729 Injection and HRS9531 Injection in Participants With Metabolic Dysfunction-Associated SteatohepatitisRecruitingNCT07660848Phase 2
• A Phase III Study To Evaluate the Efficacy And Safety Of HRS9531 In Participants With Atherosclerotic Cardiovascular DiseaseRecruitingNCT07551492Phase 3
• A Study to Evaluate the Pharmacokinetics of HRS9531 Injection in Participants With Mild, Moderate, and Normal Hepatic FunctionRecruitingNCT07540754Phase 1
• Efficacy and Safety of HRS9531 in Participants With Type 2 Diabetes Treated With Basal InsulinRecruitingNCT07060456Phase 3
• A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) TherapyRecruitingNCT06994650Phase 3
• A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and ObesityRecruitingNCT06974851Phase 3
• A Study of HRS9531 Injection in Obese Subjects With Obstructive Sleep ApneaNot yet recruitingNCT06565871Phase 2
• Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have DiabetesActive, not recruitingNCT07458269Phase 2
• A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With ObesityActive, not recruitingNCT07285902Phase 3
• Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have DiabetesActive, not recruitingNCT07284979Phase 3
• Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and DiabetesActive, not recruitingNCT07284901Phase 3
• Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have DiabetesActive, not recruitingNCT07284875Phase 3
• The Evaluation of Bioequivalence Between a Single-dose Pen and a Multi-dose Pen of HRS9531 Injection SolutionCompletedNCT06792955Phase 1
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-4729 Injection in Healthy SubjectsCompletedNCT06762600Phase 1
• Influence of HRS9531 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin in Healthy SubjectsCompletedNCT06723691Phase 1
• Influence of HRS9531 on Pharmacokinetics of Metformin in Healthy SubjectsCompletedNCT06654960Phase 1
• the Efficacy and Safety of HRS9531 Injection in Subjects With Type 2 Diabetes， Inadequately Controlled With Diet and Exercise AloneCompletedNCT06650007Phase 3
• A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 DiabetesCompletedNCT06649344Phase 3
• A Multicenter, Randomized, Double-blind, Placebo-parallel-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of HRS9531 Injection in Obese Subjects With Polycystic Ovary SyndromeStatus unknownNCT06595797Phase 2
• A Study of Single and Multiple Doses HRS9531 Tablets in Healthy SubjectsCompletedNCT06435676Phase 1
• To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects With Overweight or ObeseCompletedNCT06396429Phase 3
• HRS9531 Injection in Obese Subjects With Heart Failure With Preserved Ejection FractionActive, not recruitingNCT06391710Phase 2
• HRS9531 Controls Weight Regain in Obese SubjectsActive, not recruitingNCT06287437Phase 2
• A Study of HRS9531 in Participants With Impaired Kidney Function and Healthy SubjectsCompletedNCT06246175Phase 1
• Efficacy and Safety of HRS9531 Injections in Overweight or Obese SubjectsCompletedNCT06054698Phase 2
• Efficacy and Safety of HRS9531 Injection in Type 2 Diabetes SubjectsCompletedNCT05966272Phase 2
• A Relative Bioavailability Study of HRS9531 in Healthy SubjectsCompletedNCT05893576Phase 1
• A Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Obese Subjects Without DiabetesCompletedNCT05881837Phase 2
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Subcutaneous Injections of HRS9531 in Patients With Type 2 Diabetes MellitusCompletedNCT05516966Phase 1
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HRS9531 in Healthy SubjectsCompletedNCT05152277Phase 1

← Ribupatide overview